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The recently discovered voltage-sensitive phosphatases
(VSPs) hydrolyze phosphoinositides upon depolarization of the
membrane potential, thus representing a novel principle for the
transduction of electrical activity into biochemical signals.
Here, we demonstrate the possibility to confer voltage sensitivity to cytosolic enzymes. By fusing the tumor suppressor PTEN
to the voltage sensor of the prototypic VSP from Ciona intestinalis, Ci-VSP, we generated chimeric proteins that are voltagesensitive and display PTEN-like enzymatic activity in a strictly
depolarization-dependent manner in vivo. Functional coupling
of the exogenous enzymatic activity to the voltage sensor is
mediated by a phospholipid-binding motif at the interface
between voltage sensor and catalytic domains. Our findings
reveal that the main domains of VSPs and related phosphoinositide phosphatases are intrinsically modular and define structural requirements for coupling of enzymatic activity to a voltage sensor domain. A key feature of this prototype of novel
engineered voltage-sensitive enzymes, termed Ci-VSPTEN, is
the novel ability to switch enzymatic activity of PTEN rapidly
and reversibly. We demonstrate that experimental control of
Ci-VSPTEN can be obtained either by electrophysiological techniques or more general techniques, using potassium-induced
depolarization of intact cells. Thus, Ci-VSPTEN provides a
novel approach for studying the complex mechanism of activation, cellular control, and pharmacology of this important
tumor suppressor. Moreover, by inducing temporally precise
perturbation of phosphoinositide concentrations, Ci-VSPTEN
will be useful for probing the role and specificity of these messengers in many cellular processes and to analyze the timing of
phosphoinositide signaling.

Many cellular processes, ranging from secretion of hormones
and neurotransmitters to gene transcription, can be triggered
by rapid changes in membrane potential. The canonical principle for transduction of membrane potential changes into intra-
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cellular signals involves Ca2⫹ influx by activation of voltagegated channels, resulting in an increase of the intracellular
Ca2⫹ concentration, which in turn acts via downstream Ca2⫹sensitive proteins as effectors (1–3). The recent discovery of
voltage-sensitive phosphatases (VSPs)4 (4, 5) has broadened
this view fundamentally. In response to depolarization of the
membrane potential, the prototypic VSP from Ciona intestinalis, Ci-VSP (5, 6), degrades both phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) and phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) by removing the phosphate group in
position 5 of the inositol ring (5– 8). These phosphoinositides
are signaling molecules with pivotal roles in the regulation of
various cellular processes such as cell proliferation and differentiation (9, 10), ion channel activity (11), synaptic exocytosis
and endocytosis (12, 13), and neural development (9). Thus,
VSPs constitute a novel mechanism of coupling of intracellular
pathways to electrical activity at the plasma membrane,
although their physiological role remains elusive.
VSPs are homologues of the tumor suppressor PTEN (phosphatase and tensin homolog deleted from chromosome 10) (14,
15), a key regulator of phosphoinositide signaling pathways.
PTEN is a cytosolic 3⬘-phosphoinositide phosphatase, acting as
an antagonist of the Akt/PI3K pathway. Loss-of-function mutations of PTEN are frequently found in human cancer, ranking
this protein as one of the most important tumor suppressors
known presently (16). Regulation of PTEN activity is highly
complex, but in contrast to VSPs, it is independent of membrane potential because PTEN is a cytosolic protein. Because
the membrane lipid PI(3,4,5)P3 is the main substrate of PTEN,
binding to the plasma membrane is a prerequisite for enzymatic
activity. Targeting to the plasma membrane is mediated by two
distinct domains located in the N and C termini (17–20). The C
terminus harbors a C2 domain that binds phosphatidylserine;
its binding affinity is regulated by phosphorylation (19, 21). The
N terminus constitutes a phosphoinositide-binding motif
(PBM) that recruits PTEN to the membrane by specifically
binding to PI(4,5)P2, the main catalytic product of PTEN (17,
22). Moreover, binding of the PBM to PI(4,5)P2 allosterically
activates PTEN (17, 22). Thus, the activity of PTEN relies not
4

The abbreviations used are: VSP, voltage-sensitive phosphatase; CD, catalytic domain; OK, opossum kidney; PBM, phosphoinositide binding motif;
PD, phosphatase domain; PH, pleckstrin homology domain; PI(4,5)P2,
phosphatidylinositol(4,5)bisphosphate; PI(3,4)P2, phosphatidylinositol(3,4)bisphosphate; PI(3,4,5)P2, phosphatidylinositol(3,4,5)trisphosphate;
PI(4)P, phosphatidylinositol 4-phosphate.
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only on the recognition of its substrate but also on binding to
the membrane and on a membrane-delimited allosteric interaction with PI(4,5)P2, which acts as an activating ligand. This
complexity poses substantial challenges for further detailed
examination of the mechanism of activation, enzymatic mechanism, and regulation of PTEN and of its multiple cellular functions (23). A robust method for experimental control of PTEN
activity, analogous to the voltage control of the VSPs, might
therefore greatly facilitate such examination.
In VSPs, voltage sensitivity is conferred by a voltage-sensing
domain (VSD) located in the N terminus, which, in turn, controls the activity of the catalytic domain (CD) located within the
C terminus (see Fig. 1A). Both domains are fully functional
when expressed individually (5, 24). The modular nature of
both domains suggested that the VSD initiates the catalytic
activity by operating a molecular switch intrinsic to the CD.
The N terminus of the CD of Ci-VSP also contains a PBM
highly homologous to the PBM of PTEN (see Fig. 1B), which is
critical for depolarization-triggered activity. In fact, it has been
proposed that the mechanism of activation of the Ci-VSP
involves binding of the PBM to the membrane (8, 24); accordingly, voltage sensitivity relies on the control of this binding
step by the VSD. Thus, activation of VSPs resembles the PBMmediated activation of PTEN. Moreover, the CD of Ci-VSP
shares substantial sequence conservation with PTEN (8, 25). A
structural homology model for the CD of Ci-VSP (see Fig. 1C)
based upon the crystal structure of PTEN as a template (26)
confirmed a high degree of structural similarity between CiVSP and PTEN, including an architecture consisting of a phosphatase domain (PD) and a C2 domain. These considerations
suggested that it may be possible to impose voltage control
upon PTEN if it was connected properly to a VSD. Following
this idea, we here describe the successful generation and characterization of engineered voltage-activated enzymes (VEnz),
by conferring voltage sensitivity upon the cytoplasmic signaling
enzyme PTEN.

EXPERIMENTAL PROCEDURES
Generation of Ci-VSPTEN Chimera and Mutagenesis—CiVSPTEN chimeras were built by swapping the DNA fragments
encoding the codons 240 –576 (Ci-VSPTEN0), 255–576 (CiVSPTEN16), and 260 –576 (Ci-VSPTEN21) of Ci-VSP by the
DNA fragments encoding the codons 1– 403 (Ci-VSPTEN0),
16 – 403 (Ci-VSPTEN16), and 21– 403 (Ci-VSPTEN21) of the
mouse PTEN cDNA.5 For this, we employed a PCR-based
primer extension strategy. Briefly, the PTEN DNA fragments
were generated by PCR-amplification from a Sport6 plasmid
containing the full-length PTEN cDNA. The 5⬘ ends of the
sense and antisense primers used for these PCR were complementary to the 5⬘ and 3⬘ regions immediately flanking the
sequence to swap in the Ci-VSP cDNA. The obtained PCR
products were purified and used as extended primers for a sec-

5

PTEN from both human and mouse displays 96% identity in their nucleotide
sequence, while only differing in a single amino acid in the distal region of
the C terminus, particularly a Serine in position 398, instead of a Threonine,
as in human. To our knowledge, there is no evidence showing any difference between the activities of these two enzymes.
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ond PCR reaction using a standard QuikChange mutagenesis
protocol (Stratagene). The DNA template used for these second
PCR was a pBSTA plasmid encoding the Ci-VSP cDNA under
the T7 promoter. For expression in CHO and opossum kidney
(OK) cells, Ci-VSPTEN chimeras were subcloned from pBSTA
into pRFP-C1. Ci-VSPTEN mutants were generated by standard site-directed mutagenesis and verified by sequencing. Sensing current recordings and voltage clamp fluorometry, were
performed with Ci-VSPTEN containing the additional mutation C363S, equivalent to the catalytically inactive mutant
C124S in PTEN.
Expression in Xenopus Oocytes—The DNA was linearized
with NotI and transcribed using T7 RNA polymerase. 50 nl of
0.5–1 g/l RNA was injected per oocyte, followed by incubation at 18 °C in a solution containing 100 mM NaCl, 2 mM KCl,
1 mM MgCl2, 1.8 mM CaCl2, 2 mM sodium pyruvate, 50 M
EDTA, and 10 mM HEPES, pH 7.5 (27).
Sensing Currents and Voltage Clamp Fluorometry—Sensing
currents were measured 2– 4 days after injection with the cutopen oocyte voltage clamp technique (28) as described by Villalba-Galea et al. (27). Currents were measured in response to
voltage steps (400 ms, 10-s interval) from a holding potential of
⫺80 mV without leak subtraction during acquisition. Capacitance transient currents were compensated analogically using
the amplifier compensation circuit. The external recording
solutions contained 120 mM NMG-MeSO3 (methanesulfonate), 10 mM HEPES, and 2 mM CaCl2, pH 7.4, whereas internal
solutions contained 120 mM NMG-MeSO3, 10 mM HEPES, and
2 mM EGTA, pH 7.4. Labeling of oocytes with tetramethylrhodamine-5-maleimide and fluorometry were done as described
previously (29). Briefly, tetramethylrhodamine-5-maleimide
fluorescence was measured through a BX51WI microscope
(Olympus) equipped with a LUMPlanFl 40⫻ water immersion
objective (numerical aperture, 0.80) and an appropriate filter
set. Fluorescence intensity was monitored with a PhotoMax201-PIN photodiode controlled by a PhotoMax 200 amplifier
(Dagan). Electrophysiological and fluorescence data were filtered at 2–5 kHz and sampled at 5–20 kHz and recorded and
analyzed with the acquisition system and programs described
previously (27).
Expression in CHO and OK Cells—CHO and OK cells were
grown as described (7, 30), plated onto glass-bottomed dishes
(WillCo Wells B. V., Amsterdam, The Netherlands) or glass coverslips, respectively, and transfected using jetPEI (CHO cells;
Polyplus Transfection, Illkirch, France) or Lipofectamine 2000
(OK cells; Invitrogen). Experiments were done 24 –48 h posttransfection on cells selected for expression of mRFP-Ci-VSPTEN
and the presence of corresponding sensing currents. Vectors used
for transfection were as follows: PLC␦1-PH-pEGFP-N1 (GenBank
accession no. P51178); Akt1-PH-pEGFP-N1 (GenBank accession
no. AAL55732.1); Btk-PH-pEGFP (GenBank accession no.
AAC51347.1); OSBP-PH-pEGFP-N1 (GenBank accession no.
NP_002547.1); TAPP1-PH-FUGW (GenBank accession no. NP_
067635); bovine phosphatidylinositol 3-kinase p110␣ (constitutively active mutant K227E; GenBank accession no. NP_776999.1);
and hTASK-3-pcDNA3.1 (GenBank accession no. NP_057685).
Combined Patch Clamp and TIRF Microscopy—CHO cells
were whole-cell voltage clamped with an EPC-10 amplifier conVOLUME 286 • NUMBER 20 • MAY 20, 2011
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trolled by PatchMaster software (HEKA, Lambrecht, Germany). Sensing currents were isolated using a P/-10 protocol.
Patch pipettes were pulled from a quartz glass to an open
pipette resistance of 1.5– 4.0 M⍀ when filled with intracellular
solution: 135 mM KCl, 2.5 mM MgCl2, 2.41 mM CaCl2, 5 mM
EGTA, 5 mM HEPES, and 3 mM Na2ATP, pH 7.3 (with KOH).
For perforated patch measurements Nystatin (100 g/ml) was
added. The extracellular solution contained the following: 144
mM NaCl, 5.8 mM KCl, 0.7 mM NaH2PO4, 5.6 mM glucose, 1.3
mM CaCl2, 0.9 mM MgCl2, and 10 mM HEPES, pH 7.4 (with
NaOH). For depolarization by K⫹, cells were initially kept in
standard extracellular solution, and depolarization was induced
by transient application of 150 mM K⫹ (150 mM KCl, 5.6 mM
glucose, 1.3 mM CaCl2, 0.9 mM MgCl2, and 10 mM HEPES, pH
7.4). Total internal reflection fluorescence (TIRF) imaging was
done as described previously (7). Briefly, a BX51WI upright
microscope (Olympus) equipped with a TIRF condenser
(numerical aperture, 1.45; Olympus) and a 488-nm laser (20
milliwatt; Picarro, Sunnyvale, CA) was used. Fluorescence was
imaged through a LUMPlanFI/IR 40⫻/0.8 numerical aperture
water-immersion objective. Images were acquired with a TILLImago QE cooled CCD camera (TILL Photonics, Gräfelfing,
Germany) controlled by TILLvision software (TILL Photonics).
Imaging data were analyzed using TILLvisION and IgorPro
(Wavemetrics, Lake Oswego, OR). Regions of interest encompassed the footprint of a single cell excluding cell margins to
avoid movement artifacts. F/F0 traces were calculated from the
background-corrected TIRF signal intensity F, averaged over
the region of interest and the initial fluorescence intensity F0
during the baseline interval. F/F0 traces were corrected for
bleaching according to monoexponential fits to the baseline
interval.
Confocal Imaging—OK cells were co-transfected with mRFPCi-VSPTEN16, Akt-PH-GFP, p110␣(K227E), and the TASK3
potassium channel. Cells were transiently depolarized by application of 150 mM K⫹. Confocal imaging was performed with a
Zeiss Examiner upright microscope equipped with a LSM710
scan head (Carl Zeiss AG, Jena, Germany) and a W-Plan-Apochromat 20⫻/1.0 DIC M27 75 mm (Carl Zeiss AG). Laser lines
used were 561 nm for mRFP and 488 nm for GFP, detection
wavelength ranges were 582–754 and 493–582 nm, respectively. Time series recordings were taken in the GFP channel.
Fluorescence (F) was averaged from regions of interest placed
in cytosolic regions of individual cells and normalized to the
baseline fluorescence (F0), prior to stimulation.
All experiments were performed at room temperature. Data
are given as means ⫾ S.E.

RESULTS
Designing Chimeras between Ci-VSP and PTEN—A chimera,
hereafter named Ci-VSPTEN16, was built by replacing the CD
of Ci-VSP with full-length PTEN (Fig. 1D). Because the PBM is
critically involved in mediating activation both in Ci-VSP and
PTEN, we particularly focused our attention on the motif linking PTEN to the VSD in the chimeras. Previous functional analysis showed that, in Ci-VSP, the VSD seems to control the binding of the PBM to the membrane, and this process is critically
dependent on arginines 253 and 254. In fact, mutation of these
MAY 20, 2011 • VOLUME 286 • NUMBER 20

CD

A
Ci-VSP

VSD

PBM

PD

C2

PTEN

B

240

260
21

1

C

D

Ci-VSP(CD)

PTEN

Ci-VSPTEN 0

VSD

Ci-VSPTEN 16

VSD

PB

Ci-VSPTEN 21

VSD

PBM

FIGURE 1. Design of chimeras between Ci-VSP and PTEN. A, comparison of
the domain organization of Ci-VSP and PTEN. P, PDZ-binding motif. B, high
sequence identity between the PBMs of Ci-VSP and PTEN. Numbers refer to
the amino acid positions in Ci-VSP and PTEN, respectively. C, structural similarity between the catalytic domains of Ci-VSP and PTEN predicted by structural homology modeling of the CD of Ci-VSP (left panel) based on the crystal
structure of PTEN (26), generated with ESyPred3D (48). PD and C2 domains
are displayed in blue and green, respectively. Partially rendered PBMs are
shown in red, with arginines 253 and 254 in Ci-VSP and arginines 14 and 15 in
PTEN emphasized as stick models. Cysteines 363 (in Ci-VSP) and 124 (in PTEN)
in the catalytic core are displayed as yellow stick models. D, design of CiVSPTEN chimeras. PTEN replaces the CD of Ci-VSP with different variants of
the PBM (see text).

arginines eliminates coupling between electrical and catalytic
activity (8, 24) even if the charges are conserved (8). In addition,
arginines 245 and 246 are also critical for coupling since neutralization of these residues renders coupling inefficient (8).
Despite overall similarity, the PBM of PTEN lacks the arginines
equivalent to 245 and 246 of Ci-VSP, displaying no net charge at
the corresponding position (Fig. 1B). To account for potential
relevance of these residues for coupling of PTEN to the VSD, we
replaced the DNA sequence coding from amino acid 17 of the
PBM from Ci-VSP (including Arg245/246), with the coding
sequence of PTEN contributing the more distal part of the PBM
(Ci-VSPTEN16; see Fig. 1, B and D).
In addition to positions Arg245/246, there are further differences in the sequences of the PBMs from Ci-VSP and PTEN
(see Fig. 1B), which may be relevant for coupling between VSD
and PD. In fact, some of these amino acids are known to have a
critical impact on the function of PTEN (18, 20, 31). To account
for a potential impact of these residues on electrochemical coupling, we designed two additional chimeras containing either
the full-length PBM (i.e. 21 residues) of Ci-VSP (termed CiVSPTEN21) or the full PBM of PTEN without contribution
from the PBM of Ci-VSP (Ci-VSPTEN0) (see Fig. 1D).
Ci-VSPTEN16 Displays Voltage-activated Enzymatic Activity—
Enzymatic activity of Ci-VSPTEN16 was assessed in living cells
by imaging genetically encoded fluorescent phosphoinositide
probes, following paradigms established previously for Ci-VSP
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 2. Ci-VSPTEN displays voltage-activated lipid phosphatase activity. A, schematic representation of the enzymatic activity of PTEN, a 3⬘-phosphatase that converts PI(3,4,5)P3 into PI(4,5)P2 and PI(3,4)P2 into PI(4)P. GFP-fused sensor domains used in this study to detect concentration changes of the
putative substrates and products of Ci-VSPTEN chimeras are indicated (green). B, TIRF images of a living CHO cell coexpressing the PI(3,4,5)P2/PI(3,4)P2 sensor
Akt-PH-GFP and Ci-VSPTEN16 together with constitutively active PI3K p110␣K227E (PI3K). Images were acquired before (left) and after 30 s of depolarization to
⫹80 mV (right) in whole-cell configuration. Depolarization-induced loss of fluorescence results from reduced membrane association of Akt-PH and indicates
depletion of 3⬘-phosphoinositides. C, depolarization-induced translocation of Akt-PH as in B is followed by slow recovery, indicating resynthesis of 3⬘-phosphoinositides by PI3K (recordings obtained with perforated patch configuration). The gray area indicates depolarization from ⫺60 to ⫹80 mV. D, normalized
TIRF intensities in response to repetitive depolarization obtained as in B. Cells coexpressed Akt-PH-GFP, PI3K, and the Ci-VSPTEN chimeras indicated (n ⫽ 10, 3,
and 7 cells, for Ci-VSPTEN16, Ci-VSPTEN21, and Ci-VSPTEN16-C363S, respectively). E–H, depolarization-triggered changes in membrane association of fluorescent probes that specifically bind various phosphoinositides, measured as in D. Cells expressed Ci-VSPTEN16 together with PI3K and either Btk-PH-GFP (n ⫽ 16),
TAPP1-PH-GFP (n ⫽ 5), PLC␦1-PH-GFP (n ⫽ 6), or OSBP-PH-GFP (n ⫽ 6). Error bars indicate S.E.

(7). Briefly, membrane association of these probes reports the
abundance of the specifically recognized lipid. Membrane association was determined by TIRF imaging of cells under wholecell voltage clamp.
Upon depolarization (to ⫹80 mV), cells co-expressing CiVSPTEN16 and the probe Akt-PH-GFP, specific for PI(3,4,5)P3
and PI(3,4)P2, displayed an unambiguous decrease in membrane-associated fluorescence intensity (Fig. 2, B and C). This
observation showed that the concentration of PI(3,4,5)P3
and/or PI(3,4)P2 decreased during depolarization, indicating
that Ci-VSPTEN16 has depolarization-triggered enzymatic
activity. Following repolarization, the membrane-associated
fluorescence recovered, indicating resynthesis of PI(3,4,5)P3
and/or PI(3,4)P2 (Fig. 2C). Activation of Ci-VSPTEN16 was
rapidly reversible, as fluorescence decrease was observed only
during depolarization and ceased upon repolarization to ⫺60
mV, as demonstrated using double-pulse protocols (Fig. 2D).

17948 JOURNAL OF BIOLOGICAL CHEMISTRY

Similar results were obtained with Ci-VSPTEN21 but not with
the catalytically inactive mutant Ci-VSPTEN16-C363S (this
mutation is equivalent to C124S in PTEN) (Fig. 2C), confirming
that the fluorescence decrease was caused by enzymatic activity
of the PTEN domain of the chimeras.
The decrease in Akt-PH-GFP TIRF fluorescence obtained
with Ci-VSPTEN16 after 60 s of depolarization (⫹80 mV) was
to 46.8 ⫾ 7.2% of the initial signal (n ⫽ 5). Because a signal
decrease to ⬃40% reports the full translocation of an initially
fully membrane-resident probe (7), this finding indicates that
Ci-VSPTEN16 can completely deplete the pool of PI(3,4,5)P3
and PI(3,4)P2 in the plasma membrane.
Ci-VSPTEN16 Preserves PTEN Substrate Selectivity—Having
found that Ci-VSPTEN16 is both active and voltage-dependent, we next examined the catalytic specificity of this chimera
using other phosphoinositide-specific probes (Fig. 2A). When
co-expressed with Btk-PH-GFP or TAPP1-PH-GFP (32), which
VOLUME 286 • NUMBER 20 • MAY 20, 2011
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FIGURE 3. Effect of the PBM on the voltage sensor dynamics. A, voltage dependence of the sensing currents of the three Ci-VSPTEN chimeras were
measured from Xenopus oocytes (27), using the catalytically inactive mutant C363S (equivalent to C124S in PTEN). Normalized Q-V curves were derived
from the OFF sensing currents at ⫺90 mV following a 400-ms step to the potentials indicated. The gray curve shows the voltage dependence of
Ci-VSP-C363S recorded under the same conditions (27). Fits of a two-state Boltzmann distribution to the data (continuous red lines) yielded potentials
at half-maximal charge transfer of ⫺7 ⫾ 0.2 mV (n ⫽ 4), ⫹67 ⫾ 0.4 mV (n ⫽ 3), and ⫹69 ⫾ 0.3 mV (n ⫽ 4), with charges of 2.0 ⫾ 0.03 e0, 1.2 ⫾ 0.02 e0 and
1.1 ⫾ 0.01 e0, for Ci-VSPTEN0, Ci-VSPTEN16, and Ci-VSPTEN21, respectively. B, OFF sensing currents of Ci-VSPTEN chimeras measured at ⫺90 mV
following a 400-ms test pulse to 0 mV for Ci-VSPTEN0 and ⫹100 mV for Ci-VSPTEN16 and Ci-VSPTEN21. Current scale bars, 50 nA, 250 nA, and 100 nA,
respectively. C, Weighted mean time constants of tail-sensing currents recorded as in A are shown for the nearly saturating region of the Q-V curves
(Q/Qmax ⬎ 0.75; n ⫽ 5) for Ci-VSPTEN (black), Ci-VSPTEN16 (red), and Ci-VSPTEN21 (blue). D and E, sensing currents and changes in fluorescence intensity
(⌬F/F0) from tetramethylrhodamine-5-maleimide-labeled Ci-VSPTEN0-G214C-C363S (D) and Ci-VSP-G214C-C363S (E) in response to depolarizing voltage steps (⫺120 to 140 mV).

specifically bind PI(3,4,5)P3 and PI(3,4)P2, respectively,
Ci-VSPTEN16 evoked a decrease in membrane fluorescence
upon depolarization (Fig. 2, E and F). Thus Ci-VSPTEN16
dephosphorylates both PI(3,4,5)P3 and PI(3,4)P2, consistent
with the enzymatic activity of PTEN (Fig. 2A). Conversely,
membrane fluorescence from the PI(4,5)P2-specific probe,
PLC␦1-PH-GFP (33), increased during depolarization (Fig.
2G). This result indicated production of PI(4,5)P2 from
PI(3,4,5)P3 and confirmed that Ci-VSPTEN16 behaves as a
3⬘-phosphatase. Membrane association of PLC␦1-PH-GFP
recovered rapidly following deactivation of Ci-VSPTEN,
which most likely reflects rapid turnover of PI(4,5)P2 (7, 34)
and indicates that the PI(4,5)P2 concentration is regulated
independent of the PI(3,4,5)P3 pool depleted by Ci-VSPTEN.
Despite dephosphorylation of PI(3,4)P2, membrane fluorescence of the PI(4)P specific probe OSBP-PH-GFP (35)
seemed unaffected by depolarization (Fig. 2H), indicating
the lack of substantial changes of the PI(4)P concentration
by Ci-VSPTEN16 activation. However, this is expected,
because the basal PI(3,4)P2 content of the membrane is typically 1000-fold lower than its PI(4)P content (36). Based on
these observations, we conclude that Ci-VSPTEN16 retains
the enzymatic specificity of PTEN.
MAY 20, 2011 • VOLUME 286 • NUMBER 20

Role of PBM in Coupling Exogenous Enzymatic Activity to
Voltage Sensor—To understand the coupling of catalytic
activity to membrane potential, we next characterized the
behavior of the VSD. Thus, we measured sensing currents
from the chimeras carrying the mutation C363S expressed in
Xenopus oocytes. Sensing currents are mainly produced by
the movement of charged residues within the putative fourth
trans-membrane segment (S4) of the VSD (5). The net sensing charge movement versus potential relationship (Q-V
curve) revealed that both Ci-VSPTEN16 and -21 display
voltage dependences similar to Ci-VSP (Fig. 3A). However, a
shift to negative potentials was observed for Ci-VSPTEN0.
In addition, Ci-VSPTEN0 displayed much slower OFF-sensing currents than Ci-VSPTEN16 and Ci-VSPTEN21 (Fig. 3,
B and C). We further examined the movement of the S4
segment using voltage clamp fluorometry. Tetramethylrhodamine-5-maleimide was attached covalently to a cysteine
replacing glycine 214 in the extracellular end of this segment, such that S4 movements result in fluorescence intensity changes (27, 37). Ci-VSP (Fig. 3E) and Ci-VSPTEN0 (Fig.
3D) displayed voltage-dependent fluorescence changes with
strikingly different kinetics during repolarization: consistent
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FIGURE 4. Basal PI-3ⴕ-phosphatase activity of Ci-VSPTEN0 at resting
membrane potential. A, membrane association of the PI(3,4)P2 probe
TAPP1-PH-YFP in cells either coexpressing Ci-VSPTEN0 (n ⫽ 47 cells from nine
independent experiments) or Ci-VSPTEN0 with the inactivating mutation
C363S (n ⫽ 35 cells from 10 experiments) was imaged by TIRF microscopy.
H2O2 (1 mM) was applied for 15 min, followed by application of DTT (5 mM) for
15 min as indicated. B, average time constants obtained from monoexponential fits to the signal recovery upon application of DTT from the same experiments shown in A. Error bars indicate S.E.

with sensing currents (upper panels), fluorescence signals
(lower panels) were much slower for Ci-VSPTEN0.
Ci-VSPTEN0 Displays High Basal Activity—Despite an
intact catalytic domain, Ci-VSPTEN0 produced no changes in
membrane-associated fluorescence of Akt-PH-GFP during
depolarization (data not shown). This might be a consequence
of a strong negative shift in the voltage dependence of enzymatic activity in parallel with the voltage sensor behavior (Fig.
3A). Such a shift may render Ci-VSPTEN0 active at resting
potential and thereby preclude additional depletion of
PI(3,4,5)P3 and PI(3,4)P2 upon depolarization. However, we did
not succeed in detecting depolarization-induced enzymatic
activity even after prolonged hyperpolarization to abolish any
activity present at resting membrane potential. We therefore
tested for basal activity of Ci-VSPTEN0 under conditions of
experimentally increased substrate concentration. To this end,
cells were treated with H2O2, which is known to strongly
increase the plasma membrane concentration of PI(3,4)P2 (32,
38). The H2O2-triggered pathway leading to the PI(3,4)P2
increase is not well understood but appears to involve the dysregulation of endogenous enzymes that otherwise control
PI(3,4)P2 levels, likely including inactivation of PTEN (32). It
should be noted that H2O2 also inactivates PTEN, and consequently Ci-VSPTEN0, by formation of a disulfide bond between
Cys71 and catalytic Cys124, corresponding to Cys310 and Cys363
in the chimera (39). However, this inactivation is readily
reversed in the presence of DTT (39). When H2O2 was applied
to cells expressing Ci-VSPTEN0 and the PI(3,4)P2 sensor
TAPP1-PH, accumulation of PI(3,4)P2 was readily detected as
an increase in membrane association of TAPP-PH-GFP (Fig.
4A). Subsequent application of DTT to reverse oxidative inactivation induced a rapid decrease of membrane fluorescence in
cells expressing Ci-VSPTEN0, indicating consumption of
PI(3,4)P2. In contrast, in cells expressing the inactive mutant
Ci-VSPTEN0-C363S, recovery of PI(3,4)P2 after H2O2 treatment was delayed and occurred much more slowly (Fig. 4A).
Time constants obtained from monoexponential fits to the fluorescence decay upon application of DTT quantitatively con-
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FIGURE 5. Binding of the PBM is essential for phosphatase activation by
the VSD. Mutations that interfere with membrane binding of the PBM
(R253A/R254A and R253K/R254K) abolish the depolarization-induced activation of enzymatic activity of Ci-VSPTEN16 as monitored by measuring membrane association of Akt-PH-GFP (n ⫽ 7 cells for each mutant). Experiments
were done as described in the legend to Fig. 2, and data for Ci-VSPTEN16 are
from Fig. 2D for comparison. The gray area indicates depolarization from ⫺60
to ⫹80 mV.

firmed the faster depletion of PI(3,4)P2 with wild-type CiVSPTEN0 (Fig. 4B).
In conclusion, the fast removal of PI(3,4)P2 upon treatment
with DTT provides direct evidence for enzymatic activity of
Ci-VSPTEN0 under basal conditions, i.e. at resting membrane
potential. Additionally, the increase of PI(3,4)P2 during H2O2
application was slightly stronger and faster in cells expressing
Ci-VSPTEN0. This finding might be explained by a lower initial
concentration of PI(3,4)P2, which is again consistent with basal
activity of Ci-VSPTEN0.
Mutations in PBM Abolished Ci-VSPTEN16 Activity—Both
the effect of the PBM on the VSD movement (Fig. 3) and the
differential enzymatic activity of Ci-VSPTEN16 versus
Ci-VSPTEN0 are consistent with a pivotal role of the PBM in
electrochemically coupling the exogenous enzymatic activity to
the VSD movement. We directly tested this suggestion by
introducing mutations that have been shown previously to
affect the activity of PTEN, namely of Arg14/15 of the PBM (15,
17). The corresponding amino acids (Arg253/254) were also
shown to be critical for electrochemical coupling of Ci-VSP (8,
24). Conversion of arginines Arg14/Arg15 of the PBM to alanines or lysines completely abolished voltage-activated enzymatic activity of Ci-VSPTEN16 (Fig. 5), despite functionality of
the VSD as confirmed by sensing currents (data not shown).
This demonstrates functional uncoupling of the CD from the
VSD, confirming the essential role of the PBM for activation of
exogenous catalytic domains by a VSD.
Activation of Ci-VSPTEN16 in Intact Cells without Electrophysiological Instrumentation—So far, we have shown that CiVSPTEN allows the activation of PTEN enzymatic activity and
the depletion of both PI(3,4,5)P3 and PI(3,4)P2 when used with
electrophysiological single-cell techniques. Obviously, methods for controlling enzymatic activity with more general methods that can also be used on cell populations would substantially increase the range of potential applications.
We therefore explored K⫹-induced depolarization as a
means to activate Ci-VSPTEN16. Thus, we transiently depolarized the membrane potential by application of high extracellular K⫹ concentration to otherwise undisturbed cells
coexpressing Ci-VSPTEN16 and Akt-PH-GFP. K⫹-induced
depolarization triggered rapid depletion of both PI(3,4,5)P3 and
PI(3,4)P2 as reported by translocation of Akt-PH-GFP from the
VOLUME 286 • NUMBER 20 • MAY 20, 2011
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FIGURE 6. Experimental control of Ci-VSPTEN activity in intact cells without use of electrophysiological instrumentation. A, reversible dissociation
of Akt-PH from the plasma membrane upon K⫹-induced depolarization
observed with Ci-VSPTEN16 (n ⫽ 30 cells from five independent experiments)
but not with the catalytically inactive Ci-VSPTEN16-C363S (n ⫽ 29 cells, from
five independent experiments), measured by TIRF microscopy. CHO cells
were cotransfected with Ci-VSPTEN16, Akt-PH-GFP, PI3K, and the potassium
channel TASK3. B, confocal images of OK cells show reversible translocation of
Akt-PH from the plasma membrane to the cytosol upon K⫹-induced depolarization. OK cells were cotransfected as described in A. C, averaged time course
of K⫹-induced translocation of Akt-PH-GFP obtained from experiments as
described in B (n ⫽ 19 cells from two independent experiments).

membrane into the cytosol measured either by TIRF (Fig. 6A)
or confocal microscopy (Fig. 6, B and C). Upon lowering the
extracellular concentration of K⫹ back to the initial condition,
Akt-PH-GFP reassociated to the membrane, indicating resynthesis of PI(3,4,5)P3 and PI(3,4)P2. These results show that CiVSPTEN can be activated precisely and in a readily reversible
manner by simply altering the extracellular concentration of
K⫹.

DISCUSSION
The recently discovered VSPs constitute a novel principle for
the transduction of cellular electrical activity into intracellular
biochemical signals, which differs fundamentally from the
canonical principle for such transduction, i.e. influx of Ca2⫹
mediated by voltage-gated channels. Here, we explore molecular details of this novel principle and show that at least one
exogenous enzyme can be operated by a voltage sensor domain.
Specifically, fusing the VSD of Ci-VSP to PTEN, a key cytosolic
modulator of intracellular signaling, yielded chimeric proteins
that renders strictly voltage-dependent PTEN-like activity. To
our knowledge, both Ci-VSPTEN16 and -21 represent the first
MAY 20, 2011 • VOLUME 286 • NUMBER 20

example of conferring voltage control to a cytoplasmic enzyme,
and they constitute the first generation of engineered VEnz.
Potential Applications for Engineered VEnz—We note that
dramatically improving experimental control over PTEN activity provides a novel paradigm for the study of this important
signaling enzyme. Stringent control of activity will enable
addressing details of the enzymatic mechanism, cellular regulation, disease-causing mutations, and pharmacology of PTEN.
Beyond analysis of PTEN operation, voltage-controlled
enzymes such as Ci-VSPTEN provide novel tools for analyzing
cellular signaling. By inducing rapid phosphoinositide concentrations changes, Ci-VSPTEN can be used to probe the role and
specificity of these messengers in many cellular processes and
to analyze the timing of phosphoinositide signaling. Various
methods have been used previously to address the roles of phosphoinositides in the control of cellular function. For example,
overexpression and knockdown of enzymes involved in phosphoinositide synthesis or homeostasis have been used widely
(40 – 42). Many fundamental cellular processes occurring at a
variety of time scales are affected by phosphoinositides, including protein targeting, cell differentiation, and transcription.
Therefore, with the above-mentioned methods, it may often be
difficult to unequivocally define the direct role of these lipid
messengers for the process under observation. Moreover, compensatory mechanisms may complicate the actual changes of
phosphoinositide concentrations resulting from long term
manipulation of synthesis or degradation (43). To overcome
these problems, methods for triggered recruitment of enzymes
and signaling molecules to the plasma membrane by rapamycin-induced dimerization have been developed (43, 44). Such
recruitment has been used to induce rapid, albeit irreversible,
alterations of phosphoinositide concentrations during experimental observation (43, 44).
Voltage-controlled activation of enzymes, as introduced
here, takes this approach one step further by rapidly switching
enzymatic activity “on” and “off.” Thus, the precisely timed and
reversible control of enzyme activation on a time scale of milliseconds provides a powerful tool for addressing temporal characteristics of signaling processes. Unlike the rapamycin-based
approach, reversibility of activation allows the graded titration
of phosphoinositide concentrations in the living cell (Fig. 2D)
(7). Moreover, the recovery of phosphoinositide concentrations
following a step-like perturbation (Fig. 2C) can yield unique
insights into synthesis, homeostasis, and regulation of these
messengers (7, 34). In analogy to Ci-VSPTEN, we envisage that
fusion of different enzymatic domains to a VSD could provide
novel tools for the temporally precise interference with diverse
signaling pathways in the living cell, allowing for the experimental manipulation of cellular signaling networks beyond the
level possible with the current cell biological or biochemical
techniques.
Which enzymes or enzymatic domains may be amenable to
functional coupling to VSDs? Here, we show that membrane
binding of the PBM is critical for the activation of the exogenous enzymatic domain. The strong impact of the PBM on
voltage sensor movement indicates that the VSD activates the
exogenous enzyme by controlling the membrane binding of the
PBM (see below), resembling electrochemical coupling in
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native VSPs (8, 24). Although it has been shown that binding of
the PBM to PI(4,5)P2 increases the ␣-helicity of PTEN (22), it
remains unknown whether activation occurs by the reorientation of the PD toward its membrane-resident substrate or by
direct interaction of the PBM with the catalytic site. Although
further work is needed to distinguish between these mechanisms, the latter model would suggest that generation of VEnz
may be limited to CDs whose intrinsic activation mechanism
involves a PBM-like motif. Such candidates may include, without being limited to, additional PTEN-related proteins, namely
TPTE (45), TPIP (46), and PLIP (47). In vitro, these molecules
may possess phosphoinositide phosphatase activities with distinct substrate specificities (46, 47). Generation of VEnz chimera with these proteins may substantially help to address their
function in intact cells, which has been largely unexplored.
Mechanism of Coupling in Engineered VEnz—The loss of
electrically triggered enzymatic activity observed with PBM
mutants (Fig. 5) clearly demonstrates that electrochemical coupling in Ci-VSPTEN16 involves the PBM. How might the PBM
mediate the interaction of VSD and PD? For PTEN, it has been
shown that the PBM mediates both membrane binding and
activation of catalytic activity (17, 19, 20). Likewise, work on
Ci-VSP suggested that binding of the PBM to the plasma membrane is involved in coupling and that VSD movement modulates the PBM binding to control enzymatic activity (8, 24).
Thus, sensor movement following depolarization is thought to
promote membrane binding of the PBM and thereby activate
the PBM. According to this model, the membrane binding of
the PBM will reciprocally affect voltage sensor movement. Specifically, binding of the PBM upon depolarization will restrict
subsequent voltage sensor movement upon repolarization, thus
slowing down OFF sensing currents (8, 24).
Our present results with Ci-VSPTEN chimeras are consistent with this idea. Thus, mutations in the PBM most probably
abrogate electrochemical coupling by interfering with membrane binding, similar to previous results obtained with Ci-VSP
(8). We further observed that the full PBM from PTEN drastically slowed down voltage sensor return to the resting state
upon repolarization, when compared with both of the other
chimeras. According to the model outlined above, this observation suggests distinct membrane binding affinities of the different chimeric PBMs, with the full PBM of PTEN (i.e.
Ci-VSPTEN0) exhibiting the strongest binding.
Following this idea, the proposed distinct membrane binding
affinities may point to a specific interaction between the different PDs and their associated PBM. Thus, we note that the chimeric PBMs of Ci-VSPTEN16 and 21 yielded the fastest OFFsensing currents, which may indicate that their bound
conformation is less stable compared with native PBMs of CiVSP or Ci-VSPTEN0 associated with their original PDs (Fig. 3
and Ref. 8). These combined observations suggest that for optimal membrane binding, the PBM must match the catalytic
domain with which they couple. In this view, the PBM in CiVSP serves as an adapter for the binding between the membrane and the CD. Combinatorial exchange of PBMs in VSP
chimeras designed to operate as Ci-VSPTEN should help in
directly addressing such specific interaction of PBM and PD.
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One caveat to this model comes from its failure to fully
explain the apparent lack of control of the VSD over the CD in
Ci-VSPTEN0. The basal activity at negative potentials may
either indicate that PTEN is constitutively active at all potentials (i.e. uncoupled from the VSD) or that the activation range
is also shifted to negative potentials, as found for the sensing
current. Both scenarios are not mutually exclusive and may be
consistent with a higher membrane binding affinity of the PBM
of PTEN. For the first case, it is plausible that the control of the
VSD can be overridden by a strong interaction between the
membrane and the PBM. For the second case, the shift in voltage dependence may prevent the sensor from adopting a conformation in which the PBM cannot bind (as in the case of
Ci-VSPTEN16, -21 and other VSPs at negative potentials),
resulting in high basal activity.
Furthermore, it should be noted that the observed shift in the
voltage dependence of Ci-VSPTEN0 might be explained by an
alternative scenario, in which the PBM influences the profile of
the focused electrical field across the voltage sensor. In this
case, the PBM could increase the sensitivity of the VSD to depolarization and therefore self-promote the activation of the catalytic activity, rendering a high basal activity. To distinguish
between these different possibilities, further work is required,
which is beyond the scope of the current study.
In Ci-VSP, cationic residues Arg245, Arg246, Arg253, and
Arg254 within the PBM are involved in electrochemical coupling, presumably by contributing to binding to negatively
charged phospholipids in the membrane (8, 24). It is therefore
remarkable that the PBM from PTEN, although lacking the
positive charge at residue pair 245–246 (R245K-R246E; see Fig.
1B), produced slowed OFF-sensing currents and enhanced
enzymatic activity at resting potentials, both consistent with
enhanced membrane binding according to the coupling mechanism proposed above. This finding supports the idea that the
PBM binds to membrane lipids in a stereo-specific manner
rather than simply by electrostatic interaction with the membrane (8). This conclusion also is consistent with the elimination of electrochemical coupling by isocoulombic substitution
of Arg253 and Arg254 to Lys (Fig. 5). Further detailed analysis of
the role of individual residues within the PBM for membrane
binding is required to fully resolve this issue.
In conclusion, we have been able to engineer a series of chimeric proteins conferring voltage sensitivity to the tumor suppressor PTEN in vivo. This work supports the idea that the PBM
is a key element in the activation of VSP. In a broader view, this
study constitutes a proof-of-concept to a novel approach for
controlling enzymatic activity using VSDs.
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